This program will cover FDA-approved antibody-drug conjugate indicated for treatment of metastatic breast cancer. The results of the Phase 3 clinical trials of DESTINY-Breast04 and Destiny-Breast03 alongside of key safety considerations for ENHERTU.
The discussion will be led by Amit Patel from Astera Cancer Care.
RSVP to Marlo Aisenberg marlo.aisenberg@astrazeneca.com
Please RSVP by January 22nd.